P2X7 Рецептор рентгеновских заболеваний: общие молекулярные механизмы и терапевтические последствия.

Introduction

Rare diseases (RDs) are typically defined by very low prevalence, but the exact numerical thresholds differ substantially across countries and regions. As a result, some conditions are classified as rare in certain populations yet not in others, leading to inconsistencies in epidemiological estimates, health policy and resource allocation. 1 In a systematic analysis of 1109 institutional definitions covering 296 RDs, Richter et al proposed a global threshold of approximately 40–50 per 100,000 inhabitants as a more realistic prevalence cut-off. 2 More than 6000 distinct RDs have been described, and their combined point prevalence is estimated at 3.5–5.9% of the world population, corresponding to roughly 263–446 million affected individuals. 3

Patients with RDs face multiple challenges throughout the diagnostic and therapeutic journey. Clinically, heterogeneous presentations and limited physician experience lead to frequent under-diagnosis, misdiagnosis and substantial diagnostic delay. Therapeutically, only about 5% of RDs currently have approved treatments, and even when disease-specific therapies exist, access is often constrained by high costs and geographic disparities. 4 Consequently, RDs severely impair patients’ quality of life and impose a considerable burden on healthcare systems and societies.

With the advent of genomic technologies and the establishment of data-sharing platforms such as GeneMatcher, Matchmaker Exchange and MyGene2, the field has moved beyond purely descriptive nosology toward mechanistic dissection and cross-disease comparison. 5 In parallel with gene discovery, increasing attention has been directed to convergent molecular pathways that might be “reused” across clinically distinct RDs, offering prospects for therapeutic repurposing and platform-based drug development. Among these, the purinergic P2X7 receptor (P2X7R) has attracted particular interest. P2X7R is an ATP-gated ligand-gated cation channel 6 primarily expressed in immune-related cells such as dendritic cells, 7 macrophages, 8 T lymphocytes, 9 and glial cells. 10 It senses danger signals, such as elevated extracellular ATP levels, and promotes cation influx while perturbing Ca 2+ homeostasis, thereby triggering ROS production, 11 mitochondrial dysfunction, 12 and NLRP3 inflammasome activation. This ultimately facilitates the release of proinflammatory cytokines such as IL-1βand IL-18, leading to inflammatory amplification and tissue damage. 8 , 13 , 14 Accumulating evidence suggests that P2X7R is involved not only in the pathological processes of rare diseases but also in cardiovascular disorders 15 such as atherosclerosis and myocardial ischemia-reperfusion injury, in which its activation may contribute to endothelial injury, 16 macrophage foam cell formation, 17 and plaque inflammation. 18 In tumor-associated inflammation, the interaction between P2X7R and ATP may exert both anti-tumor and pro-tumor effects. 19 In neurodegenerative diseases such as Alzheimer’s disease(AD) and Glaucoma, 20 , 21 P2X7R may also promote microglial activation and exacerbate neuroinflammatory responses. The above evidence suggests that P2X7R is not merely an accompanying inflammatory molecule but may also play a significant pathological regulatory role in various diseases. Previous reviews have also indicated that, in basal ganglia disorders, purinergic receptors (particularly A 2 A and P2X7) may form a shared molecular platform linking Huntington’s disease and Parkinson’s disease through disturbances in Ca 2+ signaling and neuroinflammation. 22–25

Inspired by this concept, the present review focuses on P2X7R in RDs. We summarize the structural and functional properties of P2X7R, then examine its involvement in selected rare neurological, inflammatory and metabolic diseases. We further highlight convergent and divergent P2X7R-mediated pathways across these entities and discuss the emerging potential of P2X7R as a diagnostic, prognostic and therapeutic target within a precision medicine framework for RDs.

Structure, Activation, and Functional Roles of P2X7 Receptors

Structural Features of P2X7R

P2X7 receptor (P2X7R) is an ATP-gated ionotropic member of the P2X receptor (P2XR) family. In mammals, functional P2X7R is primarily assembled as homotrimers and only rarely forms heterotrimers. 6 , 26–28 The receptor is composed of three subunits, and each P2X7R subunit comprises two transmembrane domains (TM1 and TM2), a large extracellular loop, and intracellular N-terminal and extended C-terminal domains. Each subunit contains 595 (or 594) amino acid residues, 6 with the extracellular domain (282 amino acids across three subunits) being rich in cysteine and possessing three potential ATP-binding sites. Through extensive intersubunit interactions, the extracellular domain adopts a cup-shaped conformation, and occupancy of at least two binding sites is typically sufficient to activate the receptor. 10 , 29 Each P2X7R subunit contains two transmembrane helices, TM1 and TM2, each approximately 24 amino acids in length; at the trimeric level, the receptor comprises six α-helices in total, with TM1 positioned peripherally and TM2 lining the central ion-conducting pore. 30 The cytoplasmic components include the intracellular N-terminus (26 amino acids) and the extended C-terminus (residues 356–595), collectively referred to as the cytoplasmic cap, 31 which is implicated in P2X7R gating, desensitization, and large-pore formation. The N-terminus contains a protein kinase C (PKC) phosphorylation consensus sequence, which contributes to receptor gating, conformational regulation, and downstream signaling 32 , 33 The C-terminus of P2X7R is the longest within the P2X receptor (P2XR) family and represents one of its most distinctive structural features. This domain contains a cysteine-rich cytoplasmic region (also known as the C-cys anchor region, at the C-terminal end of TM2) 32 , 34 and a cytoplasmic ballast region (an additional ~120 residues at the C-terminus). 35 , 36 CCryo-electron microscopy studies have shown that C-cys functions as a molecular hinge, with its palmitoyl groups anchoring TM2 to the inner pore lining and the cytoplasmic domain to the inner leaflet of the lipid membrane, thereby helping to preserve receptor activity and delay desensitization, which endows P2X7R with sustained signaling capability. 34 Additionally, the unique C-terminal tail is associated with macropore formation and increased plasma membrane permeability. 37 Experiments have shown that the C-terminal domain of full-length rat P2X7R undergoes marked conformational rearrangement upon ATP binding, which may promote pore formation. Furthermore, researchers have identified a binuclear zinc-ion complex and a high-affinity guanylate-binding site in the cytoplasmic vestibule, providing new insights into the future functional characterization of P2X7R. 34 , 38

Activation and Pore Formation of P2X7R

The activation of P2X7R is multifactorially regulated by ligand binding, allosteric modulation, post-translational modifications, and protein-protein interactions. 15 , 37 Among these factors, high extracellular ATP is the primary endogenous agonist, and ATP sensitivity differs markedly among species. It has been reported that rat P2X7R is the most ATP-sensitive (EC 50 ~0.1–0.3 mM), mouse P2X7R exhibits intermediate sensitivity (EC 50 ~0.7–1.2 mM), and human P2X7R is the least sensitive, with an initial activation EC 50 >1 mM and, in some buffers, exceeding 2.5 mM. 39–41 The activation potency of the nucleotide analog BzATP is up to 30-fold higher than that of ATP, making it one of the most potent P2X7R agonists. BzATP also exhibits marked species-dependent differences in potency: the EC 50 is approximately 7–16 μM in rats, 58–132 μM in mice, and 170–254 μM in humans. 39 Divalent cations such as Ca 2+ and Mg 2+ can act as allosteric inhibitors that modulate receptor activity, 42–44 whereas compounds such as LL-37, 45 ivermectin, 46 ginsenosides, 47 and LPS 15 , 48 can increase P2X7R sensitivity to ATP or lower the ATP concentration threshold required for activation. In addition, Panx1-mediated hemichannel opening is also one of the classical signaling pathways associated with P2X7R activation. Panx1 is a plasma membrane hemichannel protein. 49 , 50 Under pathological conditions, inflammatory stimuli such as LPS, 51 and TNF-α 52 can promote Panx1 opening by activating caspase-11 in mice or caspase-4/5 in humans, which cleave the C-terminal domain of Panx1, thereby facilitating ATP efflux and establishing a positive feedback loop with P2X7R. 51 , 53 Conversely, the ionic imbalance induced by P2X7R activation may enhance Panx1 channel activity and increase membrane permeability, thereby exacerbating ATP release and disruption of ionic homeostasis, ultimately creating a permissive environment for inflammasome assembly and activation. 54–56

Under pathological conditions such as tissue damage, 57 infection, or oxygen-glucose deprivation (OGD), 58 elevated extracellular ATP levels can activate P2X7R. Upon activation, P2X7R briefly opens a non-selective cation channel, causing Na + , Ca 2+ influx and K + efflux. 34 Under sustained ATP stimulation, P2X7R forms a distinctive large pore that permits the passage of hydrophilic molecules with molecular weights of up to approximately 900 Da, thereby increasing plasma membrane permeability to larger solutes. 59–61 This channel not only mediates the uptake of cationic dyes such as YO-PRO-1 and ethidium bromide but also facilitates the cellular entry of anionic dyes, such as Lucifer Yellow and carboxyfluorescein. However, the permeability of large pores to molecules of different charges is influenced by multiple factors. Existing experimental evidence suggests that their selectivity for different molecules may be affected by cell type, experimental temperature, and the involvement of related pathways, such as Cl- and Panx1 channel. 38 , 60 , 62–64

Physiological and Pathological Roles of P2X7R

P2X7R is involved in a wide range of physiological and pathological processes, including inflammation, 15 pain, 65 , 66 cell proliferation and differentiation, 67 as well as the regulation of apoptosis, 68 pyroptosis, 14 necroptosis, 69 and autophagy. 70 In microglia, P2X7R activation induces K + efflux, thereby promoting the assembly of the NLRP3 inflammasome with ASC and pro-caspase-1, leading to caspase-1 activation; Activated caspase-1 also cleaves pro-GSDMD to generate gasdermin D (GSDMD), which forms membrane pores and, in concert with P2X7R-associated signaling pathways, promotes the release of IL-1β and IL-18, ultimately induces pyroptosis. 8 , 13 , 71 , 72 Meanwhile, Ca 2+ influx and aberrant activation of store-operated calcium entry (SOCE) can lead to ROS accumulation, 73 impairment of antioxidant defense, and mitochondrial dysfunction, 74 thereby inducing cytochrome c release and activation of caspase-3, −8, and −9. 12 , 75 , 76 P2X7R can also promote the biogenesis and release 65 of microglial exosomes through membrane depolarization and cytoskeletal remodeling, 77 , 78 thereby allowing inflammatory signals to spread to adjacent neurons and glial cells 78 , 79 P2X7R activation can also promote glutamate release, 80 induce excitotoxicity, and, in the presence of TNF-α, 74 trigger necroptotic cell death, thereby exacerbating neuronal injury. Outside the central nervous system, in antigen-presenting cells 81 such as macrophages and dendritic cells, P2X7R activation promotes cell maturation and upregulates MHC class I/II and co-stimulatory molecules such as CD80/CD86, 82 thereby enhancing antigen-presenting capacity and inflammasome-associated IL-1βand IL-18 production. This in turn drives the polarization of naive CD4 + T cells toward Th1/Th17 effector phenotypes and influences CD8 + T-cell activation, Treg-to-Th17 transdifferentiation, and Tfh-cell survival. 83 , 84 On the other hand, P2X7R can also enhance APC cross-dressing by promoting plasma membrane remodeling and exosome-mediated transfer of antigen-MHC complexes, thereby amplifying direct antigen presentation and indirect antigen recognition pathways. This process is particularly important in contexts such as viral infection, antitumor immunity, and transplant rejection. 7 , 9 , 85 , 86

The structural features, activation mechanisms, and major downstream signaling pathways of P2X7R are summarized in Figure 1 . As our understanding of P2X7R structure, physiology and disease involvement has grown, this receptor has evolved from being viewed merely as an “inflammatory channel” to a promising therapeutic target in multiple conditions. The following sections synthesize current evidence on P2X7R-mediated mechanisms in specific RDs and attempt to distill cross-disease commonalities. Figure 1 Structural features, activation mechanisms, and major downstream signaling pathways of the P2X7R. A pathway diagram illustrating the structural features, activation mechanisms, and major downstream signaling pathways of the P2X7 receptor (P2X7R) across the cell membrane, cytoplasm, and nucleus. At left, an inflammatory signaling pathway is shown. Inflammatory signals lead to PAMPs and DAMPs, which activate TLR4 at the cell membrane. TLR4 subsequently activates NF-κB, which enters the nucleus and induces transcription of NLRP3, pro-IL-1β, and pro-IL-18. Caspase-1 is shown near this pathway and is connected to GSDMD. At the top, an auxiliary activation pathway is shown. LPS and TNF-α are connected to caspase-11/4/5 and Panx1, which in turn is connected to P2X7R. In the center of the membrane, P2X7R is depicted as a transmembrane channel protein with a cysteine-rich extracellular domain, two transmembrane segments (TM1 and TM2), N-termini, a C-cys anchor, a cytoplasmic ballast region, and a C-terminal tail. A labeled macroporous state is linked to P2X7R, with text, 900 Da dye permeable and a legend showing cationic dyes and anionic dyes. On the right side of the membrane, K⁺ efflux and Na⁺ and Ca2+ influx are indicated. The membrane region is also shown budding to form microvesicles and exosomes. IL-1β, IL-18, and IL-6 are labeled along an arrowed cytokine output pathway.In the lower central region, the NLRP3 inflammasome is shown as a multiprotein complex connected by arrows to the lysosome, phagolysosome, and caspase-1. Caspase-1 is further connected to the secretion of IL-1β, IL-18, and IL-6. In the upper-right boxed inset, P2X7R is connected to M1-like microglia, which are linked to exosome-mediated APC cross-dressing and subsequently to MHC-II, CD86⁺, and Th1/Th17 polarization. In the middle-right region, SOCE is connected to ROS, which is further connected to mitochondrial dysfunction. Caspase-3/8/9 are shown nearby. In the lower-right boxed inset, P2X7R is connected to glutamate release, followed by TNF-α, ultimately leading to neuronal damage. P2X7R flowchart: TLR4/NF-κB priming, P2X7R activation and pore formation, ion flux, vesicle and cytokine release, inflammasome activation, immune-cell polarization, and neuronal damage. Notes : Top middle (P2X7R structure): P2X7R is an ATP-gated cation channel composed of two transmembrane domains (TM1 and TM2), a cysteine-rich extracellular domain, an intracellular N-terminal region, and a uniquely C-terminal tail.//Left to right (activation mechanisms and signaling pathways): Inflammatory stimuli activate the TLR4/NF-κB signaling pathway, thereby inducing the transcriptional upregulation of NLRP3, pro-IL-1β, and pro-IL-18. Extracellular ATP activates P2X7R, triggering Na⁺ and Ca 2 ⁺ influx, K⁺ efflux, and a transition of the receptor to a large pore state. P2X7R activation further promotes pannexin-1 (Panx1)-mediated ATP release, NLRP3 inflammasome assembly, caspase-1 activation, gasdermin D (GSDMD) cleavage, and the secretion of IL-1β and IL-18, ultimately leading to inflammatory cell death. Meanwhile, reactive oxygen species (ROS) production and mitochondrial dysfunction activate apoptotic pathways via caspase-3/8/9 signaling.//Upper right and lower right (physiological and pathological functions of P2X7R): P2X7R activation also induces glutamate release, neuronal injury, exosome secretion, antigen-presenting cell (APC) phenotypic modulation, and Th1/Th17 polarization. In summary, P2X7R plays a pivotal regulatory role in inflammation, neurodegenerative processes, and immune responses. Overall, P2X7R integrates ionic homeostasis disturbance, inflammasome activation, cell death pathways, and immune regulation, thereby contributing critically to the pathogenesis of neurological, immune-related, and various rare diseases.

P2X7 Receptors and Rare Diseases

Charcot–Marie–Tooth Disease and P2X7R

Charcot–Marie–Tooth disease (CMT) comprises a group of highly heterogeneous hereditary peripheral neuropathies characterized by distal muscle weakness and atrophy, sensory loss, and reduced tendon reflexes. The most prevalent subtype, CMT1A, accounts for approximately 50% of CMT cases and is caused by duplication of the PMP22 gene, leading to Schwann cell dysfunction and myelin instability, and ultimately to demyelinating pathology. 87 , 88 A recent review by Dong et al comprehensively summarized the current therapeutic landscape for CMT, covering pharmacological, gene-based, and cell-based strategies. Notably, the authors pointed out that while most therapies that have reached clinical trials are drug-based, gene-based approaches—aside from CMT2S—have yet to reach the clinical stage, highlighting the substantial translational barriers that continue to limit progress in this field. 89 Despite these efforts, no disease-modifying therapy has yet been approved, and current management remains largely supportive, relying mainly on symptomatic pharmacotherapy, orthopedic interventions, and rehabilitation. 90

Available experimental evidence suggests that P2X7R may contribute to CMT1A pathogenesis. In a CMT1A rat model, PMP22 overexpression was associated with P2X7R upregulation and increased P2X7R-mediated intracellular Ca 2 ⁺ levels in Schwann cells, which were linked to impaired myelinating capacity. 91 In the same experimental context, the selective P2X7R antagonist A438079 was well tolerated and was reported to improve molecular abnormalities, nerve conduction, and myelin structure. 92 Similarly, the diadenosine 5′,5′′′-P1,P2-diphosphate (Ap2A) isomer P18, which acts as a P2X7R antagonist and P2Y11 receptor agonist, reduced non-phosphorylated neurofilament levels and enhanced Schwann cell myelination in CMT1A dorsal root ganglion co-cultures. 93 However, these findings are derived mainly from preclinical models, and their relevance to human disease remains to be established. More broadly, P2X7R has been implicated in neurological and inflammatory disorders characterized by glial dysfunction, axonal injury, and neuroinflammatory responses, as reviewed by Burnstock and Knight. 94 This broader body of literature provides mechanistic context for considering P2X7R as a candidate target worthy of further investigation in peripheral neuropathies, including CMT1A.

An ideal therapeutic strategy for CMT1A would be to directly reduce Schwann cell PMP22 expression; however, multiple approaches aimed at downregulating PMP22 have not yet translated into effective therapies in humans. 95 In this context, pharmacological blockade of P2X7R may represent a complementary preclinical strategy to limit Ca 2 ⁺ overload and inflammatory signaling and thereby improve Schwann cell function. Further studies are needed to define the role of P2X7R-centered signaling networks in CMT1A and to determine whether these preclinical observations can be translated into clinically meaningful benefits.

Guillain–Barré Syndrome and P2X7R

Guillain–Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy and a leading cause of acute flaccid paralysis. Its clinical presentation is heterogeneous, but typically includes rapidly progressive limb weakness, sensory disturbances and decreased or absent deep tendon reflexes; severe cases may develop respiratory failure. First-line therapies consist of intravenous immunoglobulin (IVIg), plasma exchange and corticosteroids, yet approximately 20% of patients remain severely disabled and about 5% die despite immunotherapy. 96 , 97

The precise pathogenesis of GBS remains incompletely understood. Epidemiological data indicate that many cases are preceded by infection, including viral infections such as COVID-19, and major infectious disease outbreaks have been associated with increased GBS incidence. 98 Simões et al proposed that excessive ATP release and subsequent purinergic signaling following viral infection may be a crucial mechanistic link between infection and GBS onset, with P2X7R—especially when targeted by antagonists with favorable blood–brain barrier penetration and bioavailability—representing an attractive therapeutic candidate. 99

Xie et al reported significantly elevated P2X7R expression in peripheral blood mononuclear cells from GBS patients and in experimental autoimmune neuritis (EAN), the classical animal model of GBS. Treatment with the P2X7R antagonist Brilliant Blue G (BBG) attenuated clinical manifestations in EAN rats by modulating NLRP3 inflammasome activation and Th1/Th17 differentiation. 100 These findings suggest that P2X7R promotes aberrant inflammation and immune imbalance in GBS and may be a promising target for intervention.

Further studies are warranted to quantify the relationship between P2X7R expression, disease severity and long-term outcome, and to assess whether P2X7R involvement differs among GBS subtypes (eg AIDP vs AMAN), which would be crucial for subtype-specific and individualized therapeutic strategies.

Amyotrophic Lateral Sclerosis and P2X7R

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the degeneration of upper and lower motor neurons, leading to muscle weakness, atrophy, spasticity and paralysis, with respiratory failure being the main cause of death. Approximately 10% of cases are familial ALS (FALS), while the remainder are sporadic ALS (SALS). 101 , 102 Despite intensive research, ALS remains incurable, and current treatments offer only modest survival benefits.

P2X7R has been implicated in several ALS-related pathological processes, including neuroinflammation, glial activation, excitotoxicity and autophagy dysregulation. Post-mortem studies have demonstrated increased P2X7R immunoreactivity in microglia/macrophages in the spinal cord of ALS patients. 103 In SOD1G93A mice, a widely used ALS model, Gandelman et al showed that a neurotoxic astrocyte phenotype is dependent on basal P2X7R activation. Under pathological conditions, astrocytes sense high extracellular ATP and activate P2X7R, leading to ROS production and the release of pro-inflammatory cytokines such as IL-6, which exacerbate neuroinflammation and motor neuron injury. 104

In the same model, P2X7R activation markedly enhances NADPH oxidase 2 (NOX2) activity in microglia, driving ROS generation and neurotoxicity; these deleterious effects are reversed by genetic ablation or pharmacological inhibition of P2X7R. 105 , 106 P2X7R activation is also linked to autophagy modulation: in SOD1G93A microglia, P2X7R stimulation increases the autophagy marker LC3-II in an mTOR-dependent manner and upregulates M2-like markers. Short-term stimulation decreases SQSTM1/p62, consistent with autophagy activation, whereas prolonged stimulation increases SQSTM1/p62, indicative of impaired autophagic flux; these changes are prevented by the P2X7R antagonist A-804598 and the autophagy inhibitor wortmannin. 107 Treatment with the novel P2X7R antagonist AXX71 further demonstrated that dampening neuroinflammation and restoring autophagy can improve disease course when administered at early symptomatic stages. 108

However, not all data support a purely detrimental role of P2X7R in ALS. Reduced P2X7R expression has been reported in peripheral blood mononuclear cells from ALS patients, associated with disturbed intracellular Ca 2+ homeostasis. 109 In SOD1G93A mice, the selective P2X7 agonist BzATP exhibits protective effects on skeletal muscle by improving neuromuscular junction innervation and metabolism, and promoting satellite cell proliferation and differentiation, thereby attenuating denervation-induced atrophy. 110 Savina Apolloni et al showed that global P2X7R knockout in SOD1G93A mice aggravates disease progression, increasing motor neuron loss and gliosis and accelerating clinical decline. Interestingly, P2X7R deficiency extended lifespan by 6–7% in female but not male SOD1G93Amice, indicating sex-dependent effects. 111 Consistently, the P2X7R antagonist JNJ-47965567, when administered from the pre-symptomatic phase, delayed disease progression in female but not male SOD1G93A mice, 112 although a subsequent study with a different dosing schedule failed to replicate these benefits. 113 BBG administration further revealed that initiating treatment at late pre-symptomatic stages (around day 100) confers neuroprotective effects, whereas treatment at very early pre-symptomatic stages yields limited benefit. 114

Taken together, these findings highlight a pronounced “double-edged sword” nature of P2X7R in ALS: on the one hand, it promotes neuroinflammation and neurotoxicity; on the other, it may support protective processes in skeletal muscle and certain glial phenotypes. Rational design of P2X7R-targeted strategies in ALS must therefore consider: (i) cell- and tissue-specific roles; (ii) disease stage and therapeutic window; (iii) dose–response relationships and treatment schedules; and (iv) sex-dependent effects. Conditional knockout models and temporally controlled interventions will be crucial to enable multi-target regimens that protect both motor neurons and skeletal muscle.

Huntington’s Disease and P2X7R

Huntington’s disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by CAG trinucleotide expansion in the HTT gene, leading to the production of mutant huntingtin (mHTT). Pathologically, HD is characterized by progressive degeneration of striatal and cortical neurons, and clinically by motor disturbances, cognitive decline and psychiatric symptoms. Current therapies are largely symptomatic, and no disease-modifying treatment has been unequivocally established. 115 , 116 Therapeutic efforts are focused on lowering mHTT levels, but challenges in delivery, safety and long-term efficacy remain, underscoring the need for adjunctive neuroprotective and anti-inflammatory strategies.

Several studies have documented altered P2X7R expression and function in HD. In two different HD mouse models, striatal P2X7R levels are markedly increased, and mHTT-expressing cultured neurons exhibit heightened susceptibility to P2X7R agonist-induced apoptosis. P2X7R antagonism with BBG significantly improves motor coordination and body weight and delays disease progression in HD mice. 117 In ex vivo models, HD-associated P2X7R upregulation reshapes receptor signaling, and BzATP induces cell death and impairs synaptic transmission, effects reversed by the antagonist OxATP. 24

More recently, human post-mortem studies have shown upregulation of both full-length P2X7R (P2X7R-A) and a naturally occurring C-terminal-truncated variant (P2X7R-B) in the striatum of HD patients. Beyond increased overall mRNA, splicing patterns are altered, with slightly reduced exon 4 inclusion and significantly increased intron 10–11 retention. 118 These findings reinforce a role for P2X7R in HD pathogenesis and raise the possibility that distinct P2X7R splice variants mediate specific pathological effects.

Future research priorities in HD include: (i) dissecting the interplay between P2X7R and core pathogenic mechanisms such as mHTT aggregation, oxidative stress and mitochondrial dysfunction; (ii) evaluating combination approaches that pair P2X7R antagonists with mHTT-lowering agents (eg antisense oligonucleotides, small-molecule degraders), aiming at “causal plus protective” interventions; and (iii) investigating the impact of P2RX7 polymorphisms on HD susceptibility and treatment response to enable personalized P2X7R-based strategies.

Multiple Sclerosis and P2X7R

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system characterized pathologically by multifocal demyelination, inflammatory infiltrates and gliosis. Over time, axonal damage and loss accumulate, leading to irreversible neurodegeneration. Clinically, MS manifests as disseminated neurological deficits in space and time, with highly heterogeneous courses ranging from relapsing–remitting to progressive phenotypes. Although a broad array of disease-modifying therapies is now available, no single intervention fully addresses the complex immunoinflammatory and neurodegenerative components of MS. 119 , 120

Purinergic signaling has emerged as a relevant pathway in MS pathophysiology, with P2X7R being a particularly promising target due to its role in inflammasome activation and neurodegeneration. Post-mortem analyses have demonstrated elevated P2X7R expression in activated microglia and astrocytes within spinal cord and brain lesions of MS patients. 103 , 121 In progressive MS, increased P2X7R levels have also been reported in frontal cortical astrocytes. 122 Matute et al observed P2X7R upregulation in apparently normal-appearing fiber tracts, where enhanced ATP signaling was associated with excitotoxic damage and death of oligodendrocytes, suggesting that P2X7R-mediated changes may precede overt lesion formation. 123 Collectively, these observations support the hypothesis that P2X7R antagonists may exert protective effects by attenuating glial-mediated injury and demyelination.

In experimental autoimmune encephalomyelitis (EAE), P2X7R protein levels increase before clinical onset, initially in astrocytes, and further rise at the mRNA and protein levels as disease progresses, with higher expression also observed in neurons. 124 Early astrocyte and microglial activation precede overt neurological deficits. BBG, a commonly used P2X7R antagonist with limited selectivity, significantly reduces astrogliosis and microgliosis and delays or attenuates clinical signs in EAE animals. 125 , 126 It should be noted that some P2X7R antagonists do not exhibit absolute specificity (see Table 1 for details on the specificity, mechanisms of action, disease applications, and developmental stages of the relevant P2X7R antagonists discussed in the text). Another P2X7R antagonist not only ameliorates EAE severity but also upregulates the blood–brain barrier–related proteins claudin-5 and PDGFβR, suggesting that P2X7R blockade can help preserve barrier integrity. 127 Genetic deletion studies demonstrated that P2X7R-deficient mice show a roughly four-fold reduction in EAE incidence, with diminished astrogliosis and axonal damage compared with wild-type controls. 128 In the T cell-independent cuprizone demyelination model, P2X7R knockout reduces M1-like microglial polarization and astrogliosis, resulting in less demyelination and lower expression of inflammatory genes. 129 Table 1 Comprehensive Overview of P2X7R Antagonists: Selectivity, Mechanism, CNS Penetration, Development Stage, and Disease Relevance P2X7R Antagonists Selectivity Mechanism CNS Penetration Effect on Panx1 IC 5 0 Values of P2X7R(μM)* 130–134 Known off-Target Effects Rare Disease Indications Development Stage Major Pathological Effects Refs Human [h], Rat [r], or Mouse [m] OxATP Poor Irreversible antagonist Poor No evidence available 173–285(h) ≈ 100(m) Irreversibly modifies extracellular proteins and may affect multiple purinergic signaling pathways MS,HD Experimental research tool compound NF-κB signaling ↓; Cytokine release ↓ [ 135–138 ] BBG Moderate Non-competitive Limited Direct Panx1 inhibition 0.010–0.013(r) 0.27(h) Inhibits Panx1 channels, voltage-gated sodium channels, and P2X4 receptors at higher concentrations ALS,HD,MS,GBS,AD Preclinical proof-of-concept antagonist Neuroinflammation ↓; Microglial activation ↓; Excitotoxicity ↓; Motor neuron protection ↑ [ 75 , 139–147 ] A-740003 High Competitive antagonist Limited Indirect effect on Panx1-associated signaling 0.04 (h) 0.02 (r) Minimal reported off-target activity (IC50 >10 μM at other tested receptors, ion channels, transporters and enzymes) ALS,HD,MS Preclinical pharmacological tool compound Attenuation of neuroinflammation, IL-1β cascade, and neuropathic/inflammatory pain. [ 139 , 142 , 148–151 ] A-438079 High Competitive antagonist Limited Indirect effect on Panx1-associated signaling 0.13 (h) 0.32 (r) 2.90 (m) No major off-target activity reported; highly selective P2X7R antagonist MS,HD,CMT Preclinical pharmacological tool compound Neuroinflammation ↓; IL-1β signaling ↓ [ 152–157 ] JNJ-47965567 Very high Allosteric antagonist Good No direct evidence available 0.005–0.035 (h) 0.0047–0.098 (r) 0.00065 (m) Weak off-target activity at SERT, MT1 receptor, and CYP1A2 at micromolar concentrations HD,MS,ALS*(Mixed preclinical evidence) Translational preclinical candidate Neuroinflammation ↓; Motor neuron protection ↑ [ 38 , 39 , 158 , 159 ] JNJ-55308942 Very high Allosteric antagonist Good No direct evidence available 0.010 (h) 0.015 (r) High selectivity; potential off-target effects at high concentrations AD,HD Advanced preclinical candidate IL-1β release ↓; Microglial activation ↓; Anhedonia-like behavioral deficits ↓ [ 160–162 ] JNJ-54175446 Very high Allosteric antagonist Good No direct evidence available 0.003 (h) High selectivity; potential off-target effects at high concentrations AD Clinical-stage P2X7R antagonist (Phase II evaluation) IL-1β signaling ↓; Neuroinflammation ↓; Mood-related behavioral deficits ↓ [ 75 , 162–165 ] Notes : *1. ↓ indicates reduction, inhibition, or attenuation; ↑ indicates increase, enhancement, or protection. *2. The IC 5 0 values listed in the table are provided for reference only, as antagonist potency may vary substantially depending on the agonist used and the extracellular milieu. For example, the P2X7R inhibitory activities of oxATP and BBG may differ by 10 to 20 fold. 166 Abbreviations : BBG, Brilliant blue G; CNS, central nervous system; Panx1, Pannexin-1; AD, Alzheimer’s disease; ALS, Amyotrophic Lateral Sclerosis; GBS, Guillain-Barré syndrome; HD, Huntington’s disease; MS, Multiple Sclerosis; PD, Parkinson’s disease; CMT, Charcot-Marie-Tooth disease.

In contrast, Brosnan et al reported more severe EAE in P2X7R−/− mice, which was attributed to impaired apoptosis of autoimmune lymphocytes, leading to their persistence and aggravated autoimmune responses. 167 However, it should also be considered that P2X7R deficiency may reduce ATP-induced apoptosis of regulatory T cells, which could favor their survival and alter immune homeostasis. 168 These findings highlight a potential risk of systemic P2X7R inhibition: while it may attenuate CNS inflammation and demyelination, it could simultaneously disrupt physiological immune homeostasis by affecting both pathogenic and regulatory lymphocyte populations.

Genetic studies have further linked P2RX7 variants to MS risk and severity. Oyanguren-Desez et al found that the T allele of rs17525809, which results in an Ala-76-to-Val substitution, is more frequent in MS patients and confers a gain-of-function phenotype characterized by increased Ca 2+ influx, enhanced electrophysiological responses, and higher ethidium uptake. 169 Guerini et al genotyped 189 healthy controls and 128 MS patients (94 relapsing–remitting, 34 secondary progressive) and assessed disease severity using the Multiple Sclerosis Severity Score (MSSS). Two P2RX7 SNPs (rs1718119, Ala348Thr; rs2230912, Gln464Arg) were significantly associated with higher MSSS in relapsing–remitting MS, and both minor alleles are known gain-of-function variants. 170

Overall, P2X7R in MS fulfills dual and partly opposing roles: in CNS glia, its activation promotes inflammation and demyelination, whereas in peripheral immune cells it participates in the apoptotic clearance of harmful autoreactive lymphocytes. Clinically, a rational approach might involve preferential targeting of CNS P2X7R while preserving or even supporting beneficial peripheral immune functions. Integrating P2RX7 genotyping into patient stratification could further optimize candidate selection and dosing for P2X7R-modulating therapies.

Taken together, the evidence presented above suggests that P2X7R may contribute to the pathogenesis of these five neurological rare diseases through dysregulated calcium signaling, exacerbated inflammatory responses, glial activation, neuronal damage, myelin abnormalities, and blood-brain barrier disruption, as shown in Figure 2 . Figure 2 This schematic highlights the critical roles of the P2X7 receptor (P2X7R) in rare diseases. The diagram illustrates the role of the P2X7 receptor (P2X7R) in five rare diseases, with P2X7R shown at the center and five surrounding sections representing Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), Guillain-Barré syndrome (GBS), and multiple sclerosis (MS). In the upper-left section (CMT), PMP22 overexpression increases P2X7R activity, leading to increased intracellular Ca2+, Schwann cell dysfunction, impaired myelination in CMT1A, and cytotoxicity mediated by ROS and NOX2. In the lower-left section (ALS), extracellular ATP activates P2X7R in glial cells, promoting ROS production, IL-6 release, neuroinflammation, and motor neuron injury. P2X7R enhances NOX2 activity and regulates autophagy through the mTOR and SQSTM1/p62 pathways involving LC3-II, resulting in impaired autophagy; M1-like and M2-like macrophages are also shown. In the bottom section (HD), P2X7R expression is increased in HD models, and its activation promotes neuronal death and synaptic damage. BzATP administration is associated with cell death, while full-length P2X7R-A and truncated P2X7R-B are increased in the striatum of patients with HD. In the upper-right section (GBS), in GBS and experimental autoimmune neuritis (EAN), P2X7R levels are increased. Its activation promotes inflammasome activation and Th1/Th17 polarization, contributing to excitotoxicity and cell death. Brilliant Blue G reduces symptoms by inhibiting these processes. In the right section (MS), glial P2X7R mediates ATP-driven excitotoxicity and cell death and contributes to blood-brain barrier disruption through claudin-5 and PDGFbetaR. The rs17525809 variant alters Ca2+ permeability and is associated with enhanced electrophysiological responses and ethidium uptake. Overall, the diagram highlights P2X7R-mediated calcium signaling and inflammatory responses as potential therapeutic targets in these rare diseases. P2X7 receptor impacts rare diseases via calcium signaling dysregulation, neuroinflammation, excitotoxicity, blood-brain barrier disruption, and impaired autophagy. Notes : Upper left (CMT): PMP22 overexpression upregulates P2X7R, causing increased intracellular Ca 2 ⁺ and Schwann cell dysfunction, leading to myelination defects in CMT1A.//Lower left (ALS): Extracellular ATP activates P2X7R in glial cells, driving ROS production and IL-6 release, which exacerbate neuroinflammation and motor neuron injury. P2X7R enhances NOX2 activity and modulates autophagy via mTOR and SQSTM1/p62 pathways.//Bottom (HD): P2X7R is elevated in HD models, where its activation induces neuronal death and synaptic impairment. Both full-length (P2X7R-A) and truncated (P2X7R-B) forms increase in patient striatum.//Upper right (GBS): P2X7R levels rise in GBS and EAN models; antagonism with Brilliant Blue G reduces symptoms by inhibiting inflammasome activation and Th1/Th17 polarization.//Right (MS): P2X7R in glial cells mediates ATP-driven excitotoxicity, disrupts BBB via claudin-5 and PDGFβR regulation. The rs17525809 variant alters calcium permeability, resulting in heightened electrophysiological responses and elevated ethidium uptake. ↑ indicates enhanced function or upregulated P2X7R levels. In summary, P2X7R-mediated calcium signaling and immuno-inflammatory responses play central roles in the pathogenesis of various rare diseases, highlighting its importance as a potential therapeutic target. Abbreviations : ALS, amyotrophic lateral sclerosis; BBB, blood-brain barrier; CMT, Charcot-Marie-Tooth disease; EAN, experimental autoimmune neuritis; GBS, Guillain-Barré syndrome; HD, Huntington’s disease; IL-6, interleukin-6; MS, multiple sclerosis; NOX2, NADPH oxidase 2; ROS, reactive oxygen species; Th, T helper.

Other Rare Diseases and P2X7R

Beyond the neurological RDs described above, P2X7R may indirectly contribute to the pathogenesis or treatment response of several rare inflammatory and metabolic disorders by modulating inflammasome activation, neuronal excitability or lysosomal function.

Cryopyrin-associated periodic syndrome (CAPS) comprises a group of autoinflammatory conditions caused by NLRP3 mutations, leading to constitutive inflammasome activation and excessive IL-1β release, which in turn drives systemic inflammation. 171 Although direct evidence for an essential role of P2X7R in CAPS pathogenesis is lacking, its established function as an upstream trigger of NLRP3 inflammasomes suggests that P2X7R antagonists could dampen IL-1β production and alleviate symptoms, particularly in cases with suboptimal response to IL-1 inhibitors such as anakinra.

Familial Mediterranean fever (FMF) is an autosomal recessive periodic fever syndrome characterized by recurrent episodes of fever and serositis, most often caused by mutations in MEFV, the Mediterranean fever gene, which encodes pyrin and leads to enhanced inflammasome activity and IL-1β secretion. 172 , 173 Colchicine is the first-line therapy. Recent studies indicate that one of colchicine’s key mechanisms may be the inhibition of P2X7R-mediated pore formation, thereby indirectly suppressing inflammasome activation and IL-1β release. 174 Because P2X7R activation can promote K⁺ efflux and downstream inflammasome signaling, it may also engage pathways that converge on gasdermin D-dependent membrane pore formation and pyroptotic cytokine release. 175 , 176 However, whether colchicine directly affects gasdermin D remains unclear. Taken together, these findings suggest that P2X7R may modulate FMF disease activity and treatment response through pathways linked to inflammasome activation and pyroptosis.

Systemic sclerosis (SSc) is a multifaceted immune-mediated connective tissue disease characterized by immune dysregulation, vasculopathy, and progressive fibrosis involving the skin and multiple internal organs. Although therapeutic strategies have improved in recent years, current management remains largely organ-directed and symptomatic, with limited capacity to directly suppress the underlying fibrotic process. 177 , 178 In this context, the purinergic P2X7 receptor (P2X7R) has been reported to be associated with SSc-related inflammatory and fibrotic responses. Notably, studies in dermal fibroblasts derived from patients with SSc have shown that P2X7R is markedly upregulated and that its activation promotes calcium influx and a profibrotic phenotype, characterized by increased α-SMA expression, enhanced cell migration, and elevated collagen and CTGF production. Inhibition of the ERK pathway has been shown to abolish the pro-collagen effect of P2X7R activation, suggesting that ERK signaling may serve as a key downstream mediator. 179 Therefore, P2X7R may represent a potential therapeutic target in SSc; however, these findings were obtained in vitro (often under LPS‑primed conditions) and in studies with relatively small sample sizes, and thus require confirmation in larger cohorts and in vivo models before translational conclusions can be drawn.

Dravet syndrome (DS) is a rare, severe, drug-resistant epileptic encephalopathy with onset in infancy, classified as a developmental and epileptic encephalopathy (DEE). Approximately 80% of patients harbor SCN1A mutations. 180 Clinically, DS is characterized by multiple seizure types, intellectual disability and motor delays. Therapeutic goals focus on seizure reduction and quality-of-life improvement. P2X7R contributes to epileptogenesis via mechanisms including cell death, synaptic plasticity changes, blood–brain barrier disruption and neurotransmitter release. In animal models, P2X7R antagonists have shown anti-seizure effects. 181 , 182 Although a direct causal link between P2X7R and DS has not been established, the receptor’s roles in neuroinflammation, excitability and neuroprotection make it a plausible adjunct target. Genetically precise models could be used to assess the impact of P2X7R modulation on seizure control and developmental outcomes.

Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by GBA1 mutations leading to deficient β-glucocerebrosidase (GCase) activity and accumulation of glucocerebroside in macrophages (“Gaucher cells”), with multi-organ involvement and, in some subtypes, central nervous system degeneration. 183 Enzyme replacement therapy effectively improves many systemic manifestations of type I GD, but therapeutic options for neuronopathic forms remain limited. In addition to its well-established role in inflammation, P2X7R has been reported to modulate membrane trafficking processes, including phagosome maturation and fusion with lysosomes, exocytosis of secretory lysosomes, and the release of microvesicles and exosomes. 184 P2X7R also contributes to membrane lipid homeostasis and asymmetry by promoting phosphatidylserine externalization and loss of phospholipid asymmetry, thereby affecting membrane stability and endomembrane organization. 184 P2X7R has also been implicated in the regulation of lipophagy through the AMPK/ULK1 pathway, thereby influencing intracellular lipid accumulation and lysosomal dynamics. 185 Given that GD is characterized by glucocerebroside accumulation in macrophages, P2X7R-mediated modulation of lysosomal fusion, membrane lipid homeostasis, and lipophagy may represent additional mechanisms by which this receptor could influence disease progression. These observations further support P2X7R as a potential therapeutic target in GD, particularly for modulating lysosomal function and lipid metabolism beyond its established roles in inflammation.

Overall, current studies only suggest that P2X7R may be involved in the inflammatory regulation, altered neuronal excitability, or lysosomal and autophagic dysfunction in certain rare inflammatory or metabolic diseases. However, most of the available evidence comes from indirect mechanistic inference or preclinical studies, and the strength of evidence varies across conditions. Therefore, P2X7R is currently better considered a candidate mechanism that may contribute to the pathogenesis of selected rare diseases and warrants further validation.

Shared Molecular Mechanisms of P2X7R Across Rare Diseases

Despite striking differences in genetic etiology, target organs and clinical phenotypes, the RDs discussed above appear to converge on several P2X7R-centered mechanisms:

Ca 2+ Overload and Mitochondrial Dysfunction as a Central Hub

In CMT1A Schwann cells, peripheral nerves in GBS, CNS tissue in ALS/HD/MS and macrophages in GD, excessive P2X7R activation induces Ca 2+ influx, mitochondrial depolarization, ROS generation and engagement of cell death cascades. The Ca 2+ –mitochondrial axis thus serves as a core hub of P2X7R-mediated injury.

NLRP3 Inflammasome Activation and Chronic Inflammation

P2X7R is a well-established upstream trigger of NLRP3 inflammasome assembly. While this pathway is prototypical in gout and CAPS, similar mechanisms operate in GBS/EAN, MS/EAE, FMF and potentially in some lysosomal storage diseases: P2X7R-mediated pore formation and K + efflux facilitate NLRP3 activation and IL-1β maturation, driving Th1/Th17 polarization, glial activation and tissue damage.

Glial and Immune Cell Phenotypic Shifts

In ALS, HD and MS, P2X7R activation pushes microglia and astrocytes toward pro-inflammatory, neurotoxic phenotypes (M1-like), with increased NOX2-derived ROS and exacerbated demyelination or motor neuron death. Conversely, transient or low-level P2X7R activity may support M2-like anti-inflammatory signatures or muscle regeneration, illustrating a context-dependent dualism.

Barrier Dysfunction and Increased Tissue Vulnerability

In MS and epilepsy models, P2X7R contributes to blood–brain barrier disruption via endothelial and glial mechanisms, increasing CNS exposure to peripheral inflammatory mediators. Analogous processes may underlie blood–nerve barrier changes in GBS and CMT, facilitating immune cell infiltration and inflammatory injury.

P2RX7 Polymorphisms Shaping Disease Risk and Severity

Gain-of-function P2RX7 variants are associated with increased risk and severity in MS and may influence susceptibility and treatment responses in other RDs. This mirrors observations in basal ganglia diseases, where altered purinergic receptor expression and sensitivity modulate disease phenotypes, suggesting a more general paradigm in which genetic variation fine-tunes purinergic signaling across conditions.

Collectively, these findings support the concept that P2X7R integrates extracellular danger signals into a conserved pathological network centered on Ca 2+ , mitochondria and inflammasomes that is repeatedly “reused” across RDs. However, disease-specific factors—including the predominant P2X7R-expressing cell types, the timing and intensity of activation and interactions with primary genetic or environmental insults—determine whether P2X7R signaling is ultimately deleterious, compensatory or neutral in a given clinical context.

Conclusion and Future Directions

P2X7R occupies a strategic position at the intersection of inflammation amplification, cell death and immune regulation. Accumulating evidence links aberrant P2X7R activation or expression to the pathogenesis of multiple RDs affecting the peripheral and central nervous systems, the immune system and lysosomal function. Viewed together, these data support the notion that P2X7R-dependent pathways form a shared molecular platform across clinically heterogeneous RDs, reminiscent of the purinergic mechanisms that connect Huntington’s and Parkinson’s disease.

Several critical challenges must be addressed before P2X7R can be fully exploited as a therapeutic target: 1) The precise, context-dependent roles of P2X7R differ across diseases, cell types and stages, and the receptor often exerts both detrimental and protective effects. 2) P2X7R expression and function are influenced by genetic polymorphisms, disease stage, sex and concomitant medications, complicating both mechanistic interpretation and therapeutic design. 3) Most evidence derives from cellular and animal models, and many P2X7R antagonists have failed to meet expectations in clinical trials, highlighting translational gaps between preclinical and human studies.

Future research directions include: 1) Systematic analysis of P2X7R interactions with oxidative stress, lysosomal storage, mitochondrial dysfunction and other key pathogenic pathways using multi-omics and systems biology approaches in diverse RD models. 2) Design of CNS-penetrant, highly selective P2X7R antagonists or modulators with optimized pharmacokinetics and safety profiles to overcome the limitations of first-generation compounds. 3) Incorporation of P2RX7 genotyping and inflammatory/neurodegenerative biomarkers into patient stratification, enabling personalized selection of candidates, dosing regimens and combination therapies. 4) Use of organoids, microphysiological systems and gene-editing technologies to create models that more faithfully recapitulate human RD pathology and thereby improve predictive validity for clinical translation. 5) Rationally designed clinical trials based on comparative and translational data, with careful evaluation of dosing, timing and combination regimens, supported by coordinated efforts among academia, industry, regulatory agencies and patient organizations.

In summary, substantial progress has been made in elucidating P2X7R biology in RDs, but realizing its full therapeutic potential will require sustained, multidisciplinary efforts. Clarifying when, where and how to modulate P2X7R activity may ultimately help shift the management of selected RDs from symptomatic care toward mechanism-based, precision interventions, offering new hope for this large and historically underserved patient population.

Data Sharing Statement

Data sharing is not applicable to this article as no data were created or analysed in this study.

Author Contributions

Xinyi Xiao: Conceptualization, Investigation, Writing – original draft, Data curation, Visualization.

Gege Cao and Shuai Hou: Investigation, Data curation, Writing – review & editing.

Haiyan Yin: Conceptualization, Supervision, Writing – review & editing, Funding acquisition.

All authors took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

Xinyi Xiao reports Support for the manuscript from National Natural Science Foundation of China (Key Projects), during the conduct of the study.

All authors declare that the research was conducted in the absence of any other commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Haendel M , Vasilevsky N , Unni D , et al. How many rare diseases are there? Nat Rev Drug Discov . 2020 ; 19 ( 2 ): 77 – 18 . doi: 10.1038/d41573-019-00180-y 32020066 PMC7771654

2. Richter T , Nestler-Parr S , Babela R , et al. Rare disease terminology and definitions-a systematic global review: report of the ISPOR rare disease special interest group . Value Health . 2015 ; 18 ( 6 ): 906 – 914 . doi: 10.1016/j.jval.2015.05.008 26409619

3. Nguengang Wakap S , Lambert DM , Olry A , et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database . Eur J Hum Genet . 2020 ; 28 ( 2 ): 165 – 173 . doi: 10.1038/s41431-019-0508-0 31527858 PMC6974615

4. The Lancet Diabetes Endocrinology . Spotlight on rare diseases . Lancet Diab Endocrinol . 2019 ; 7 ( 2 ): 75 . doi: 10.1016/S2213-8587(19)30006-3 30683214

5. Taruscio D , Gahl WA . Rare diseases: challenges and opportunities for research and public health . Nat Rev Dis Primers . 2024 ; 10 ( 1 ): 13 . doi: 10.1038/s41572-024-00505-1 38424095

6. Sluyter R . The P2X7 Receptor . Adv Exp Med Biol . 2017 ; 1051 : 17 – 53 . doi: 10.1007/5584_2017_59 28676924

7. Mena J , Leiva-Salcedo E , Araya-Dapremont N , et al. Rat P2X7 receptor show functional Independence between macropore formation and scavenger activity . Int J Mol Sci . 2026 ; 27 ( 4 ): 1922 . doi: 10.3390/ijms27041922 41752057 PMC12940821

8. Gao H , Wang L , Lyu Y , et al. The P2X7R/NLRP3 inflammasome axis suppresses enthesis regeneration through inflammatory and metabolic macrophage-stem cell cross-talk . Sci Adv . 2025 ; 11 ( 17 ): eadr4894 . doi: 10.1126/sciadv.adr4894 40279432 PMC12024643

9. Acuña-Castillo C , Escobar A , García-Gómez M , et al. P2X7 receptor in dendritic cells and macrophages: implications in antigen presentation and T lymphocyte activation . Int J Mol Sci . 2024 ; 25 ( 5 ): 2495 . doi: 10.3390/ijms25052495 38473744 PMC10931747

10. Zou J , Vetreno RP , Crews FT . ATP-P2X7 receptor signaling controls basal and TNFα-stimulated glial cell proliferation . Glia . 2012 ; 60 ( 4 ): 661 – 673 . doi: 10.1002/glia.22302 22298391 PMC3276752

11. Moreira-Souza ACA , Almeida-da-Silva CLC , Rangel TP , et al. The P2X7 receptor mediates toxoplasma gondii control in macrophages through canonical NLRP3 inflammasome activation and reactive oxygen species production . Front Immunol . 2017 ; 8 : 1257 . doi: 10.3389/fimmu.2017.01257 29075257 PMC5643413

12. Sekar P , Huang DY , Hsieh SL , Chang SF , Lin WW . AMPK-dependent and independent actions of P2X7 in regulation of mitochondrial and lysosomal functions in microglia . Cell Commun Signal . 2018 ; 16 ( 1 ): 83 . doi: 10.1186/s12964-018-0293-3 30458799 PMC6245559

13. Manzanares-Meza LD , Gutiérrez-Román CI , Jiménez-Pineda A , et al. IL-36γ is secreted through an unconventional pathway using the Gasdermin D and P2X7R membrane pores . Front Immunol . 2022 ; 13 : 979749 . doi: 10.3389/fimmu.2022.979749 36059446 PMC9434278

14. Rao H , Ding Q , Liu A , Qiu H , Luo J . The synergistic role of P2rx7 and Panx1 in regulating alveolar macrophage pyroptosis and exosome-mediated ferroptosis of alveolar epithelial cells in lipopolysaccharide-induced acute respiratory distress syndrome . Faseb J . 2025 ; 39 ( 16 ): e70904 . doi: 10.1096/fj.202403385RR 40827894

15. Di Virgilio F , Dal Ben D , Sarti AC , Giuliani AL , Falzoni S . The P2X7 receptor in infection and inflammation . Immunity . 2017 ; 47 ( 1 ): 15 – 31 . doi: 10.1016/j.immuni.2017.06.020 28723547

16. Leng B , Li C , Sun Y , et al. Protective effect of astragaloside IV on high glucose-induced endothelial dysfunction via inhibition of P2X7R dependent P38 MAPK signaling pathway . Oxid Med Cell Longev . 2020 ; 2020 : 5070415 . doi: 10.1155/2020/5070415 33014270 PMC7512101

17. Peng K , Liu L , Wei D , et al. P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation . Int J Mol Med . 2015 ; 35 ( 5 ): 1179 – 1188 . doi: 10.3892/ijmm.2015.2129 25761252 PMC4380202

18. Stachon P , Heidenreich A , Merz J , et al. P2X7 deficiency blocks lesional inflammasome activity and ameliorates atherosclerosis in mice . Circulation . 2017 ; 135 ( 25 ): 2524 – 2533 . doi: 10.1161/CIRCULATIONAHA.117.027400 28377486

19. Rotondo JC , Mazziotta C , Lanzillotti C , et al. The role of Purinergic P2X7 receptor in inflammation and cancer: novel molecular insights and clinical applications . Cancers . 2022 ; 14 ( 5 ): 1116 . doi: 10.3390/cancers14051116 35267424 PMC8909580

20. Newman J . Microglial mechanisms of cell death and the role of the P2X7 receptor in relation to glaucoma . Doctoral thesis . University of East Anglia ; 2023 . https://ueaeprints.uea.ac.uk/id/eprint/95828 . Accessed August 17 , 2026 .

21. Bartlett R , Stokes L , Sluyter R . The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease . Pharmacol Rev . 2014 ; 66 ( 3 ): 638 – 675 . doi: 10.1124/pr.113.008003 24928329

22. Glaser T , Andrejew R , Oliveira-Giacomelli Á , et al. Purinergic receptors in basal ganglia diseases: shared molecular mechanisms between huntington’s and parkinson’s disease . Neurosci Bull . 2020 ; 36 ( 11 ): 1299 – 1314 . doi: 10.1007/s12264-020-00582-8 33026587 PMC7674528

23. Burnstock G . Purinergic signalling and neurological diseases: an update . CNS Neurol Disord Drug Targets . 2017 ; 16 ( 3 ): 257 – 265 . doi: 10.2174/1871527315666160922104848 27658510

24. Martire A , Pepponi R , Liguori F , Volonté C , Popoli P . P2X7 receptor agonist 2’(3’)-O-(4-Benzoylbenzoyl)ATP differently modulates cell viability and corticostriatal synaptic transmission in experimental models of huntington’s disease . Front Pharmacol . 2021 ; 11 : 633861 . doi: 10.3389/fphar.2020.633861 33679392 PMC7933594

25. Carmo M , Gonçalves FQ , Canas PM , et al. Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson’s disease . Br J Pharmacol . 2019 ; 176 ( 18 ): 3666 – 3680 . doi: 10.1111/bph.14771 31220343 PMC6715785

26. Nicke A . Homotrimeric complexes are the dominant assembly state of native P2X7 subunits . Biochem Biophys Res Commun . 2008 ; 377 ( 3 ): 803 – 808 . doi: 10.1016/j.bbrc.2008.10.042 18938136

27. Dubyak GR . Go it alone no more--P2X7 joins the society of heteromeric ATP-gated receptor channels . Mol Pharmacol . 2007 ; 72 ( 6 ): 1402 – 1405 . doi: 10.1124/mol.107.042077 17895406

28. Schneider M , Prudic K , Pippel A , et al. Interaction of purinergic P2X4 and P2X7 receptor subunits . Front Pharmacol . 2017 ; 8 : 860 . doi: 10.3389/fphar.2017.00860 29213241 PMC5702805

29. Stelmashenko O , Lalo U , Yang Y , Bragg L , North RA , Compan V . Activation of trimeric P2X2 receptors by fewer than three ATP molecules . Mol Pharmacol . 2012 ; 82 ( 4 ): 760 – 766 . doi: 10.1124/mol.112.080903 22828800 PMC3463222

30. Jiang LH , Caseley EA , Muench SP , Roger S . Structural basis for the functional properties of the P2X7 receptor for extracellular ATP . Purinergic Sig . 2021 ; 17 ( 3 ): 331 – 344 . doi: 10.1007/s11302-021-09790-x PMC8410900 33987781

31. Mansoor SE , Lü W , Oosterheert W , Shekhar M , Tajkhorshid E , Gouaux E . X-ray structures define human P2X(3) receptor gating cycle and antagonist action . Nature . 2016 ; 538 ( 7623 ): 66 – 71 . doi: 10.1038/nature19367 27626375 PMC5161641

32. Allsopp RC , Evans RJ . Contribution of the juxtatransmembrane intracellular regions to the time course and permeation of ATP-gated P2X7 receptor ion channels . J Biol Chem . 2015 ; 290 ( 23 ): 14556 – 14566 . doi: 10.1074/jbc.M115.642033 25903136 PMC4505523

33. Allsopp RC , Evans RJ . The intracellular amino terminus plays a dominant role in desensitization of ATP-gated P2X receptor ion channels . J Biol Chem . 2011 ; 286 ( 52 ): 44691 – 44701 . doi: 10.1074/jbc.M111.303917 22027824 PMC3247974

34. McCarthy AE , Yoshioka C , Mansoor SE . Full-length P2X7 structures reveal how palmitoylation prevents channel desensitization . Cell . 2019 ; 179 ( 3 ): 659 – 670.e13 . doi: 10.1016/j.cell.2019.09.017 31587896 PMC7053488

35. Cheewatrakoolpong B , Gilchrest H , Anthes JC , Greenfeder S . Identification and characterization of splice variants of the human P2X7 ATP channel . Biochem Biophys Res Commun . 2005 ; 332 ( 1 ): 17 – 27 . doi: 10.1016/j.bbrc.2005.04.087 15896293

36. Costa-Junior HM , Sarmento Vieira F , Coutinho-Silva R . C terminus of the P2X7 receptor: treasure hunting . Purinergic Sig . 2011 ; 7 ( 1 ): 7 – 19 . doi: 10.1007/s11302-011-9215-1 PMC3083127 21484094

37. Di Virgilio F , Giuliani AL , Vultaggio-Poma V , Falzoni S , Sarti AC . Non-nucleotide agonists triggering P2X7 receptor activation and pore formation . Front Pharmacol . 2018 ; 9 : 39 . doi: 10.3389/fphar.2018.00039 29449813 PMC5799242

38. Di Virgilio F , Schmalzing G , Markwardt F . The elusive P2X7 macropore . Trends Cell Biol . 2018 ; 28 ( 5 ): 392 – 404 . doi: 10.1016/j.tcb.2018.01.005 29439897

39. Donnelly-Roberts DL , Namovic MT , Han P , Jarvis MF . Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors . Br J Pharmacol . 2009 ; 157 ( 7 ): 1203 – 1214 . doi: 10.1111/j.1476-5381.2009.00233.x 19558545 PMC2743839

40. Roger S , Gillet L , Baroja-Mazo A , Surprenant A , Pelegrin P . C-terminal calmodulin-binding motif differentially controls human and rat P2X7 receptor current facilitation . J Biol Chem . 2010 ; 285 ( 23 ): 17514 – 17524 . doi: 10.1074/jbc.M109.053082 20378545 PMC2878516

41. Tewari M , Michalski S , Egan TM . Modulation of microglial function by ATP-Gated P2X7 receptors: studies in rat, mice and human . Cells . 2024 ; 13 ( 2 ): 161 . doi: 10.3390/cells13020161 38247852 PMC10814008

42. Sander S , Müller I , Garcia-Alai MM , Nicke A , Tidow H . New insights into P2X7 receptor regulation: ca2+-calmodulin and GDP bind to the soluble P2X7 ballast domain . J Biol Chem . 2022 ; 298 ( 10 ): 102495 . doi: 10.1016/j.jbc.2022.102495 36115462 PMC9574498

43. Markwardt F . Human P2X7 receptors - Properties of single ATP-gated ion channels . Biochem Pharmacol . 2021 ; 187 : 114307 . doi: 10.1016/j.bcp.2020.114307 33130127

44. Roger S , Pelegrin P , Surprenant A . Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding . J Neurosci . 2008 ; 28 ( 25 ): 6393 – 6401 . doi: 10.1523/JNEUROSCI.0696-08.2008 18562610 PMC6670894

45. Tang X , Basavarajappa D , Haeggström JZ , Wan M . P2X7 receptor regulates internalization of antimicrobial peptide LL-37 by human macrophages that promotes intracellular pathogen clearance . J Immunol . 2015 ; 195 ( 3 ): 1191 – 1201 . doi: 10.4049/jimmunol.1402845 26116509 PMC4505952

46. Nörenberg W , Sobottka H , Hempel C , et al. Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors . Br J Pharmacol . 2012 ; 167 ( 1 ): 48 – 66 . doi: 10.1111/j.1476-5381.2012.01987.x 22506590 PMC3448913

47. Cui L , Tan YJ , Xu SQ , et al. Ginsenoside Rd, a natural production for attenuating fibrogenesis and inflammation in hepatic fibrosis by regulating the ERRα-mediated P2X7r pathway . Food Funct . 2023 ; 14 ( 12 ): 5606 – 5619 . doi: 10.1039/d3fo01315d 37249244

48. Chiao CW , da Silva-Santos JE , Giachini FR , Tostes RC , Su MJ , Webb RC . P2X7 receptor activation contributes to an initial upstream mechanism of lipopolysaccharide-induced vascular dysfunction . Clin Sci . 2013 ; 125 ( 3 ): 131 – 141 . doi: 10.1042/CS20120479 PMC4004361 23469860

49. Yan Z , Li S , Liang Z , Tomić M , Stojilkovic SS . The P2X7 receptor channel pore dilates under physiological ion conditions . J Gen Physiol . 2008 ; 132 ( 5 ): 563 – 573 . doi: 10.1085/jgp.200810059 18852304 PMC2571973

50. Yang K , Xiao Z , He X , Weng R , Zhao X , Sun T . Mechanisms of Pannexin 1 (PANX1) channel mechanosensitivity and its pathological roles . Int J Mol Sci . 2022 ; 23 ( 3 ): 1523 . doi: 10.3390/ijms23031523 35163442 PMC8836264

51. Yang D , He Y , Muñoz-Planillo R , Liu Q , Núñez G . Caspase-11 requires the Pannexin-1 Channel and the Purinergic P2X7 Pore to mediate pyroptosis and endotoxic shock . Immunity . 2015 ; 43 ( 5 ): 923 – 932 . doi: 10.1016/j.immuni.2015.10.009 26572062 PMC4795157

52. Huang KC , Chiang SF , Lin PC , et al. TNFα modulates PANX1 activation to promote ATP release and enhance P2RX7-mediated antitumor immune responses after chemotherapy in colorectal cancer . Cell Death Dis . 2024 ; 15 ( 1 ): 24 . doi: 10.1038/s41419-023-06408-5 38195677 PMC10776587

53. Yin F , Zheng PQ , Zhao LQ , et al. Caspase-11 promotes NLRP3 inflammasome activation via the cleavage of pannexin1 in acute kidney disease . Acta Pharmacol Sin . 2022 ; 43 ( 1 ): 86 – 95 . doi: 10.1038/s41401-021-00619-2 33758356 PMC8724289

54. Boyce AKJ , Swayne LA . P2X7 receptor cross-talk regulates ATP-induced pannexin 1 internalization . Biochem J . 2017 ; 474 ( 13 ): 2133 – 2144 . doi: 10.1042/BCJ20170257 28495860

55. Shan Y , Ni Y , Gao Z . Pannexin-1 channel regulates ATP release in epilepsy . Neurochem Res . 2020 ; 45 ( 5 ): 965 – 971 . doi: 10.1007/s11064-020-02981-9 32170674

56. Purohit R , Bera AK . Pannexin 1 plays a pro-survival role by attenuating P2X7 receptor-mediated Ca2+ influx . Cell Calcium . 2021 ; 99 : 102458 . doi: 10.1016/j.ceca.2021.102458 34479067

57. Gulbransen BD , Bashashati M , Hirota SA , et al. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis . Nat Med . 2012 ; 18 ( 4 ): 600 – 604 . doi: 10.1038/nm.2679 22426419 PMC3321107

58. Cisneros-Mejorado A , Gottlieb M , Cavaliere F , et al. Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates postischemic damage . J Cereb Blood Flow Metab . 2015 ; 35 ( 5 ): 843 – 850 . doi: 10.1038/jcbfm.2014.262 25605289 PMC4420860

59. Cevoli F , Arnould B , Peralta FA , Grutter T . Untangling macropore formation and current facilitation in P2X7 . Int J Mol Sci . 2023 ; 24 ( 13 ): 10896 . doi: 10.3390/ijms241310896 37446075 PMC10341454

60. Janks L , Sharma CVR , Egan TM . A central role for P2X7 receptors in human microglia . J Neuroinflamm . 2018 ; 15 ( 1 ): 325 . doi: 10.1186/s12974-018-1353-8 PMC6247771 30463629

61. Dunning K , Martz A , Peralta FA , et al. P2X7 receptors and TMEM16 channels are functionally coupled with implications for macropore formation and current facilitation . Int J Mol Sci . 2021 ; 22 ( 12 ): 6542 . doi: 10.3390/ijms22126542 34207150 PMC8234106

62. Schachter J , Motta AP , de Souza Zamorano A , da Silva-Souza HA , Guimarães MZ , Persechini PM . ATP-induced P2X7-associated uptake of large molecules involves distinct mechanisms for cations and anions in macrophages . J Cell Sci . 2008 ; 121 ( Pt 19 ): 3261 – 3270 . doi: 10.1242/jcs.029991 18782864

63. Browne LE , Compan V , Bragg L , North RA . P2X7 receptor channels allow direct permeation of nanometer-sized dyes . J Neurosci . 2013 ; 33 ( 8 ): 3557 – 3566 . doi: 10.1523/JNEUROSCI.2235-12.2013 23426683 PMC6619550

64. Ugur M , Ugur Ö . A mechanism-based approach to P2X7 receptor action . Mol Pharmacol . 2019 ; 95 ( 4 ): 442 – 450 . doi: 10.1124/mol.118.115022 30737253

65. Zhang K , Ran R , Zhang CJ , Wang L , Zhang HH . Focus on P2X7R in microglia: its mechanism of action and therapeutic prospects in various neuropathic pain models . Front Pharmacol . 2025 ; 16 : 1555732 . doi: 10.3389/fphar.2025.1555732 40201695 PMC11975881

66. Li XQ , Yu Q , Zhang ZL , Sun XJ , Ma H . MiR-187-3p mimic alleviates ischemia-reperfusion-induced pain hypersensitivity through inhibiting spinal P2X7R and subsequent mature IL-1β release in mice . Brain Behav Immun . 2019 ; 79 : 91 – 101 . doi: 10.1016/j.bbi.2019.05.021 31100367

67. Grassi F . The P2X7 receptor as regulator of T cell development and function . Front Immunol . 2020 ; 11 : 1179 . doi: 10.3389/fimmu.2020.01179 32587592 PMC7297980

68. He Y , Taylor N , Fourgeaud L , Bhattacharya A . The role of microglial P2X7: modulation of cell death and cytokine release . J Neuroinflamm . 2017 ; 14 ( 1 ): 135 . doi: 10.1186/s12974-017-0904-8 PMC5513370 28716092

69. Delarasse C , Gonnord P , Galante M , et al. Neural progenitor cell death is induced by extracellular ATP via ligation of P2X7 receptor . J Neurochem . 2009 ; 109 ( 3 ): 846 – 857 . doi: 10.1111/j.1471-4159.2009.06008.x 19250337

70. Bedetta M , Pizzo P , Lia A . The multifaceted role of P2X7R in microglia and astrocytes . Neurochem Res . 2025 ; 50 ( 4 ): 239 . doi: 10.1007/s11064-025-04502-y 40690063 PMC12279596

71. Karmakar M , Minns M , Greenberg EN , et al. N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis . Nat Commun . 2020 ; 11 ( 1 ): 2212 . doi: 10.1038/s41467-020-16043-9 32371889 PMC7200749

72. Wang Y , Dong L , Zhang Y , et al. Activation of the microglial P2X7R/NLRP3 inflammasome mediates central sensitization in a mouse model of medication overuse headache . Front Mol Neurosci . 2023 ; 16 : 1177171 . doi: 10.3389/fnmol.2023.1177171 37377770 PMC10291138

73. Orfali R , Alwatban AZ , Orfali RS , et al. Oxidative stress and ion channels in neurodegenerative diseases . Front Physiol . 2024 ; 15 : 1320086 . doi: 10.3389/fphys.2024.1320086 38348223 PMC10859863

74. Zelentsova AS , Deykin AV , Soldatov VO , et al. P2X7 receptor and purinergic signaling: orchestrating mitochondrial dysfunction in neurodegenerative diseases . eNeuro . 2022 ; 9 ( 6 ): ENEURO.0092 – 22.2022 . doi: 10.1523/ENEURO.0092-22.2022 36376084 PMC9665882

75. Liu X , Li Y , Huang L , et al. Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders . Front Pharmacol . 2024 ; 15 : 1450704 . doi: 10.3389/fphar.2024.1450704 39139642 PMC11319138

76. Martínez-García JJ , Martínez-Banaclocha H , Angosto-Bazarra D , et al. P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis . Nat Commun . 2019 ; 10 ( 1 ): 2711 . doi: 10.1038/s41467-019-10626-x 31221993 PMC6586640

77. Di Giuseppe F , Ricci-Vitiani L , Pallini R , et al. Changes induced by P2X7 receptor stimulation of human glioblastoma stem cells in the proteome of extracellular vesicles isolated from their secretome . Cells . 2024 ; 13 ( 7 ): 571 . doi: 10.3390/cells13070571 38607010 PMC11011151

78. Golia MT , Gabrielli M , Verderio C . P2X7 receptor and extracellular vesicle release . Int J Mol Sci . 2023 ; 24 ( 12 ): 9805 . doi: 10.3390/ijms24129805 37372953 PMC10298639

79. Zhang J , Yu Z , Wang M , et al. Enhanced exosome secretion regulated by microglial P2X7R in the medullary dorsal horn contributes to pulpitis-induced pain . Cell Biosci . 2025 ; 15 ( 1 ): 28 . doi: 10.1186/s13578-025-01363-4 39987146 PMC11847359

80. Illes P . P2X7 receptors amplify CNS damage in neurodegenerative diseases . Int J Mol Sci . 2020 ; 21 ( 17 ): 5996 . doi: 10.3390/ijms21175996 32825423 PMC7504621

81. Grassi F , Salina G . The P2X7 receptor in autoimmunity . Int J Mol Sci . 2023 ; 24 ( 18 ): 14116 . doi: 10.3390/ijms241814116 37762419 PMC10531565

82. Wang M , Zhao X , Hou S , Wu Z , Yin HY . Purinergic Receptors in Dendritic Cells . J Inflamm Res . 2025 ; 18 : 13423 – 13432 . doi: 10.2147/JIR.S549102 41049073 PMC12495957

83. Peng X , Zhang Y , Bai X , Li X , Zhao R . Phasic regulation of the ATP/P2X7 receptor signaling pathway affects the function of antigen-presenting cells in experimental autoimmune uveitis . Int Immunopharmacol . 2023 ; 119 : 110241 . doi: 10.1016/j.intimp.2023.110241 37141671

84. Rivas-Yáñez E , Barrera-Avalos C , Parra-Tello B , et al. P2X7 receptor at the crossroads of T cell fate . Int J Mol Sci . 2020 ; 21 ( 14 ): 4937 . doi: 10.3390/ijms21144937 32668623 PMC7404255

85. Gonzalez-Nolasco B , Lancia HH , Carnel-Amar N , et al. Adenosine triphosphate-mediated signaling of P2X7 receptors controls donor extracellular vesicle release and major histocompatibility complex cross-decoration after allotransplantation . Am J Transplant . 2025 ; 25 ( 4 ): 674 – 681 . doi: 10.1016/j.ajt.2024.12.008 39694144 PMC11972886

86. Barrera-Avalos C , Briceño P , Valdés D , et al. P2X7 receptor is essential for cross-dressing of bone marrow-derived dendritic cells . iScience . 2021 ; 24 ( 12 ): 103520 . doi: 10.1016/j.isci.2021.103520 34950860 PMC8671947

87. Patzkó A , Shy ME . Update on Charcot-Marie-Tooth disease . Curr Neurol Neurosci Rep . 2011 ; 11 ( 1 ): 78 – 88 . doi: 10.1007/s11910-010-0158-7 21080241 PMC3685483

88. Pareyson D , Saveri P , Pisciotta C . New developments in Charcot-Marie-Tooth neuropathy and related diseases . Curr Opin Neurol . 2017 ; 30 ( 5 ): 471 – 480 . doi: 10.1097/WCO.0000000000000474 28678038

89. Dong H , Qin B , Zhang H , Lei L , Wu S . Current treatment methods for charcot-marie-tooth diseases . Biomolecules . 2024 ; 14 ( 9 ): 1138 . doi: 10.3390/biom14091138 39334903 PMC11430469

90. Pisciotta C , Saveri P , Pareyson D . Challenges in treating charcot-marie-tooth disease and related neuropathies: current management and future perspectives . Brain Sci . 2021 ; 11 ( 11 ): 1447 . doi: 10.3390/brainsci11111447 34827446 PMC8615778

91. Nobbio L , Sturla L , Fiorese F , et al. P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy . J Biol Chem . 2009 ; 284 ( 34 ): 23146 – 23158 . doi: 10.1074/jbc.M109.027128 19546221 PMC2755720

92. Sociali G , Visigalli D , Prukop T , et al. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy . Neurobiol Dis . 2016 ; 95 : 145 – 157 . doi: 10.1016/j.nbd.2016.07.017 27431093

93. Nobbio L , Visigalli D , Mannino E , et al. The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A . J Cell Biochem . 2014 ; 115 ( 1 ): 161 – 167 . doi: 10.1002/jcb.24644 23959806

94. Burnstock G , Knight GE . The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression . Purinergic Sig . 2018 ; 14 ( 1 ): 1 – 18 . doi: 10.1007/s11302-017-9593-0 PMC5842154 29164451

95. Morena J , Gupta A , Hoyle JC . Charcot-marie-tooth: from molecules to therapy . Int J Mol Sci . 2019 ; 20 ( 14 ): 3419 . doi: 10.3390/ijms20143419 31336816 PMC6679156

96. Shahrizaila N , Lehmann HC , Kuwabara S . Guillain-Barré syndrome . Lancet . 2021 ; 397 ( 10280 ): 1214 – 1228 . doi: 10.1016/S0140-6736(21)00517-1 33647239

97. Florian IA , Lupan I , Sur L , Samasca G , Timiș TL . To be, or not to be… Guillain-Barré Syndrome . Autoimmun Rev . 2021 ; 20 ( 12 ):102983. doi: 10.1016/j.autrev.2021.102983 34718164

98. Abu-Rumeileh S , Abdelhak A , Foschi M , Tumani H , Otto M . Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases . J Neurol . 2021 ; 268 ( 4 ): 1133 – 1170 . doi: 10.1007/s00415-020-10124-x 32840686 PMC7445716

99. Simões JLB , Bagatini MD . Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome . J Neuroimmune Pharmacol . 2021 ; 16 ( 1 ): 48 – 58 . doi: 10.1007/s11481-020-09980-1 33462776 PMC7813171

100. Xie Y , Han R , Li Y , et al. P2X7 receptor antagonists modulate experimental autoimmune neuritis via regulation of NLRP3 inflammasome activation and Th17 and Th1 cell differentiation . J Neuroinflamm . 2024 ; 21 ( 1 ): 73 . doi: 10.1186/s12974-024-03057-z PMC10964508 38528529

101. Feldman EL , Goutman SA , Petri S , et al. Amyotrophic lateral sclerosis . Lancet . 2022 ; 400 ( 10360 ): 1363 – 1380 . doi: 10.1016/S0140-6736(22)01272-7 36116464 PMC10089700

102. Ilieva H , Vullaganti M , Kwan J . Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis . BMJ . 2023 ; 383 : e075037 . doi: 10.1136/bmj-2023-075037 37890889 PMC10603569

103. Yiangou Y , Facer P , Durrenberger P , et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord . BMC Neurol . 2006 ; 6 : 12 . doi: 10.1186/1471-2377-6-12 16512913 PMC1413551

104. Gandelman M , Peluffo H , Beckman JS , Cassina P , Barbeito L . Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis . J Neuroinflammation . 2010 ; 7 : 33 . doi: 10.1186/1742-2094-7-33 20534165 PMC2901222

105. D’Ambrosi N , Finocchi P , Apolloni S , et al. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis . J Immunol . 2009 ; 183 ( 7 ): 4648 – 4656 . doi: 10.4049/jimmunol.0901212 19734218

106. Apolloni S , Parisi C , Pesaresi MG , et al. The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis . J Immunol . 2013 ; 190 ( 10 ): 5187 – 5195 . doi: 10.4049/jimmunol.1203262 23589615

107. Fabbrizio P , Amadio S , Apolloni S , Volonté C . P2X7 receptor activation modulates autophagy in SOD1-G93A mouse microglia . Front Cell Neurosci . 2017 ; 11 : 249 . doi: 10.3389/fncel.2017.00249 28871219 PMC5566572

108. Apolloni S , Fabbrizio P , Amadio S , et al. Novel P2X7 antagonist ameliorates the early phase of ALS disease and decreases inflammation and autophagy in SOD1-G93A mouse model . Int J Mol Sci . 2021 ; 22 ( 19 ): 10649 . doi: 10.3390/ijms221910649 34638992 PMC8508678

109. Liu J , Prell T , Stubendorff B , et al. Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis . Neurosci Lett . 2016 ; 630 : 77 – 83 . doi: 10.1016/j.neulet.2016.07.039 27453058

110. Fabbrizio P , Apolloni S , Bianchi A , et al. P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis . Brain Pathol . 2020 ; 30 ( 2 ): 272 – 282 . doi: 10.1111/bpa.12774 31376190 PMC7065186

111. Apolloni S , Amadio S , Montilli C , Volonté C , D’Ambrosi N . Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis . Hum Mol Genet . 2013 ; 22 ( 20 ): 4102 – 4116 . doi: 10.1093/hmg/ddt259 23736299

112. Ruiz-Ruiz C , García-Magro N , Negredo P , et al. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice . Dis Model Mech . 2020 ; 13 ( 10 ): dmm045732 . doi: 10.1242/dmm.045732 33174532 PMC7648608

113. Ly D , Dongol A , Cuthbertson P , et al. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice . Purinergic Sig . 2020 ; 16 ( 1 ): 109 – 122 . doi: 10.1007/s11302-020-09692-4 PMC7166237 32170537

114. Apolloni S , Amadio S , Parisi C , et al. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis . Dis Model Mech . 2014 ; 7 ( 9 ): 1101 – 1109 . doi: 10.1242/dmm.017038 25038061 PMC4142730

115. Saft C . Huntington’s disease: disappointments and new beginnings . Lancet Neurol . 2022 ; 21 ( 7 ): 582 – 584 . doi: 10.1016/S1474-4422(22)00189-2 35716683

116. Shannon KM , Fraint A . Therapeutic advances in Huntington’s Disease . Mov Disord . 2015 ; 30 ( 11 ): 1539 – 1546 . doi: 10.1002/mds.26331 26226924

117. Díaz-Hernández M , Díez-Zaera M , Sánchez-Nogueiro J , et al. Altered P2X7-receptor level and function in mouse models of Huntington’s disease and therapeutic efficacy of antagonist administration . FASEB J . 2009 ; 23 ( 6 ): 1893 – 1906 . doi: 10.1096/fj.08-122275 19171786

118. Ollà I , Santos-Galindo M , Elorza A , Lucas JJ . P2X7 receptor upregulation in huntington’s disease brains . Front Mol Neurosci . 2020 ; 13 : 567430 . doi: 10.3389/fnmol.2020.567430 33122998 PMC7573237

119. Lassmann H . Pathology and disease mechanisms in different stages of multiple sclerosis . J Neurol Sci . 2013 ; 333 ( 1–2 ): 1 – 4 . doi: 10.1016/j.jns.2013.05.010 23735777

120. Filippi M , Bar-Or A , Piehl F , et al. Multiple sclerosis . Nat Rev Dis Primers . 2018 ; 4 ( 1 ): 43 . doi: 10.1038/s41572-018-0041-4 30410033

121. Narcisse L , Scemes E , Zhao Y , Lee SC , Brosnan CF . The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes . Glia . 2005 ; 49 ( 2 ): 245 – 258 . doi: 10.1002/glia.20110 15472991 PMC2586293

122. Amadio S , Parisi C , Piras E , et al. Modulation of P2X7 receptor during inflammation in multiple sclerosis . Front Immunol . 2017 ; 8 : 1529 . doi: 10.3389/fimmu.2017.01529 29187851 PMC5694754

123. Matute C , Torre I , Pérez-Cerdá F , et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis . J Neurosci . 2007 ; 27 ( 35 ): 9525 – 9533 . doi: 10.1523/JNEUROSCI.0579-07.2007 17728465 PMC6673129

124. Grygorowicz T , Struzyńska L , Sulkowski G , Chalimoniuk M , Sulejczak D . Temporal expression of P2X7 purinergic receptor during the course of experimental autoimmune encephalomyelitis . Neurochem Int . 2010 ; 57 ( 7 ): 823 – 829 . doi: 10.1016/j.neuint.2010.08.021 20817062

125. Grygorowicz T , Wełniak-Kamińska M , Strużyńska L . Early P2X7R-related astrogliosis in autoimmune encephalomyelitis . Mol Cell Neurosci . 2016 ; 74 : 1 – 9 . doi: 10.1016/j.mcn.2016.02.003 26921791

126. Grygorowicz T , Strużyńska L . Early P2X7R-dependent activation of microglia during the asymptomatic phase of autoimmune encephalomyelitis . Inflammopharmacology . 2019 ; 27 ( 1 ): 129 – 137 . doi: 10.1007/s10787-018-0528-3 30209761 PMC6470107

127. Grygorowicz T , Dąbrowska-Bouta B , Strużyńska L . Administration of an antagonist of P2X7 receptor to EAE rats prevents a decrease of expression of claudin-5 in cerebral capillaries . Purinergic Sig . 2018 ; 14 ( 4 ): 385 – 393 . doi: 10.1007/s11302-018-9620-9 PMC6298928 30091000

128. Sharp AJ , Polak PE , Simonini V , et al. P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis . J Neuroinflamm . 2008 ; 5 : 33 . doi: 10.1186/1742-2094-5-33 PMC2518548 18691411

129. Bernal-Chico A , Manterola A , Cipriani R , Katona I , Matute C , Mato S . P2x7 receptors control demyelination and inflammation in the cuprizone model . Brain Behav Immun Health . 2020 ; 4 : 100062 . doi: 10.1016/j.bbih.2020.100062 34589847 PMC8474271

130. Jiang LH , Mackenzie AB , North RA , Surprenant A . Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors . Mol Pharmacol . 2000 ; 58 ( 1 ): 82 – 88 . 10860929

131. Csóka B , Németh ZH , Törő G , et al. Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing . Faseb J . 2015 ; 29 ( 9 ): 3626 – 3637 . doi: 10.1096/fj.15-272450 26060214 PMC4550379

132. Müller CE , Namasivayam V . Agonists, antagonists, and modulators of P2X7 receptors . Methods Mol Biol . 2022 ; 2510 : 31 – 52 . doi: 10.1007/978-1-0716-2384-8_2 35776318

133. El Idrissi IG , Podlewska S , Abate C , Bojarski AJ , Lacivita E , Leopoldo M . Structure-activity relationships and therapeutic potential of purinergic P2X7 receptor antagonists . Curr Med Chem . 2024 ; 31 ( 11 ): 1361 – 1403 . doi: 10.2174/0929867330666230403094538 37013427

134. Savio LEB , de Andrade Mello P , da Silva CG , Coutinho-Silva R . The P2X7 receptor in inflammatory diseases: angel or demon? Front Pharmacol . 2018 ; 9 : 52 . doi: 10.3389/fphar.2018.00052 29467654 PMC5808178

135. Beigi RD , Kertesy SB , Aquilina G , Dubyak GR . Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms . Br J Pharmacol . 2003 ; 140 ( 3 ): 507 – 519 . doi: 10.1038/sj.bjp.0705470 14522842 PMC1574058

136. Murgia M , Hanau S , Pizzo P , Rippa M , Di Virgilio F . Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor . J Biol Chem . 1993 ; 268 ( 11 ): 8199 – 8203 . 8463330

137. Maneu V , García AG . P2X7 receptors as targets for neuroprotection . Neuropharmacology . 2026 ; 289 : 110877 . doi: 10.1016/j.neuropharm.2026.110877 41672134

138. Soares-Bezerra RJ , Ferreira NC , Alberto AV , et al. An improved method for P2X7R antagonist screening . PLoS One . 2015 ; 10 ( 5 ): e0123089 . doi: 10.1371/journal.pone.0123089 25993132 PMC4437783

139. Calzaferri F , Ruiz-Ruiz C , de Diego AMG , et al. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases . Med Res Rev . 2020 ; 40 ( 6 ): 2427 – 2465 . doi: 10.1002/med.21710 32677086

140. Ferrazoli EG , de Souza HD , Nascimento IC , et al. Brilliant Blue G, but not fenofibrate, treatment reverts hemiparkinsonian behavior and restores dopamine levels in an animal model of parkinson’s disease . Cell Transplant . 2017 ; 26 ( 4 ): 669 – 677 . doi: 10.3727/096368917X695227 28403913 PMC5661224

141. Kumar S , Mishra A , Krishnamurthy S . Purinergic antagonism prevents mitochondrial dysfunction and behavioral deficits associated with dopaminergic toxicity induced by 6-OHDA in rats . Neurochem Res . 2017 ; 42 ( 12 ): 3414 – 3430 . doi: 10.1007/s11064-017-2383-9 28836128

142. Andrejew R , Oliveira-Giacomelli Á , Ribeiro DE , et al. The P2X7 Receptor: central Hub of Brain Diseases . Front Mol Neurosci . 2020 ; 13 : 124 . doi: 10.3389/fnmol.2020.00124 32848594 PMC7413029

143. Bartlett R , Sluyter V , Watson D , Sluyter R , Yerbury JJ . P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1G93A amyotrophic lateral sclerosis mice . PeerJ . 2017 ; 5 : e3064 . doi: 10.7717/peerj.3064 28265522 PMC5335685

144. Zhou X , Yang Y , Wu L , et al. Brilliant Blue G inhibits inflammasome activation and reduces disruption of blood-spinal cord barrier induced by spinal cord injury in rats . Med Sci Monit . 2019 ; 25 : 6359 – 6366 . doi: 10.12659/MSM.915865 31444877 PMC6719612

145. Qiu F , Dahl G . A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP . Am J Physiol Cell Physiol . 2009 ; 296 ( 2 ): C250 – C255 . doi: 10.1152/ajpcell.00433.2008 18945939 PMC2643853

146. Jo S , Bean BP . Inhibition of neuronal voltage-gated sodium channels by brilliant blue G . Mol Pharmacol . 2011 ; 80 ( 2 ): 247 – 257 . doi: 10.1124/mol.110.070276 21536754 PMC3141889

147. Lu K , Wang J , Hu B , et al. Brilliant blue G attenuates lipopolysaccharide-mediated microglial activation and inflammation . Neural Regen Res . 2013 ; 8 ( 7 ): 599 – 608 . doi: 10.3969/j.issn.1673-5374.2013.07.003 25206704 PMC4145984

148. Honore P , Donnelly-Roberts D , Namovic MT , et al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat . J Pharmacol Exp Ther . 2006 ; 319 ( 3 ): 1376 – 1385 . doi: 10.1124/jpet.106.111559 16982702

149. Burma NE , Bonin RP , Leduc-Pessah H , et al. Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents . Nat Med . 2017 ; 23 ( 3 ): 355 – 360 . doi: 10.1038/nm.4281 28134928

150. Almusallam N , Alonazi A , Dayel AB , et al. Antifibrotic effect of the P2X7 receptor antagonist A740003 against acute myocardial infarction-induced fibrotic remodelling . Saudi Pharm J 2024 ; 32 ( 7 ):102102. doi: 10.1016/j.jsps.2024.102102 PMC11258548 39035363

151. Janssen B , Vugts DJ , Funke U , et al. Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [ 11 C]A-740003 as a novel tracer of neuroinflammation . J Labelled Comp Radiopharm . 2014 ; 57 ( 8 ): 509 – 516 . doi: 10.1002/jlcr.3206 24995673

152. Inoue H , Kuroda H , Ofusa W , et al. Functional coupling between the P2X7 receptor and pannexin-1 channel in rat trigeminal ganglion neurons . Int J Mol Sci . 2021 ; 22 ( 11 ): 5978 . doi: 10.3390/ijms22115978 34205953 PMC8198496

153. Marcellino D , Suárez-Boomgaard D , Sánchez-Reina MD , et al. On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: studies with the P2X(7) receptor antagonist A-438079 . J Neural Transm . 2010 ; 117 ( 6 ): 681 – 687 . doi: 10.1007/s00702-010-0400-0 20387084

154. Fan X , Ma W , Zhang Y , Zhang L . P2X7 receptor (P2X7R) of microglia mediates neuroinflammation by regulating (NOD)-like receptor protein 3 (NLRP3) inflammasome-dependent inflammation after spinal cord injury . Med Sci Monit . 2020 ; 26 : e925491 . doi: 10.12659/MSM.925491 32952148 PMC7518010

155. Martiáñez Canales T . Estudio del fármaco CMP Forte y del nucleótido UTP en células de Schwann . ( 2011 ). Universitat Internacional de Catalunya; handle : https://hdl.handle.net/10803/77766 . Accessed August 17 , 2026 .

156. Hu Z , Xie S , Chen C , Luo Z , Deng X , Xiao R . Targeting the P2X7 receptor in cerebrovascular diseases: from molecular mechanisms to preclinical therapeutic potential . Front Pharmacol . 2025 ; 16 : 1713748 . doi: 10.3389/fphar.2025.1713748 41383474 PMC12689568

157. Chen SP , Qin T , Seidel JL , et al. Inhibition of the P2X7-PANX1 complex suppresses spreading depolarization and neuroinflammation . Brain . 2017 ; 140 ( 6 ): 1643 – 1656 . doi: 10.1093/brain/awx085 28430869 PMC7526725

158. Janssen B , Vugts DJ , Wilkinson SM , et al. Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation . Sci Rep . 2018 ; 8 ( 1 ): 6580 . doi: 10.1038/s41598-018-24814-0 29700413 PMC5920098

159. Bhattacharya A , Wang Q , Ao H , et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567 . Br J Pharmacol . 2013 ; 170 ( 3 ): 624 – 640 . doi: 10.1111/bph.12314 23889535 PMC3792000

160. Bhattacharya A , Lord B , Grigoleit JS , et al. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia . Neuropsychopharmacology . 2018 ; 43 ( 13 ): 2586 – 2596 . doi: 10.1038/s41386-018-0141-6 30026598 PMC6224414

161. Dias D , Socodato R . Beyond amyloid and tau: the critical role of microglia in alzheimer’s disease therapeutics . Biomedicines . 2025 ; 13 ( 2 ): 279 . doi: 10.3390/biomedicines13020279 40002692 PMC11852436

162. Territo PR , Zarrinmayeh H . P2X7 receptors in neurodegeneration: potential therapeutic applications from basic to clinical approaches . Front Cell Neurosci . 2021 ; 15 : 617036 . doi: 10.3389/fncel.2021.617036 33889073 PMC8055960

163. Chrovian CC , Soyode-Johnson A , Peterson AA , et al. A dipolar cycloaddition reaction to access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines enables the discovery synthesis and preclinical profiling of a P2X7 antagonist clinical candidate . J Med Chem . 2018 ; 61 ( 1 ): 207 – 223 . doi: 10.1021/acs.jmedchem.7b01279 29211470

164. Wang K , Huang S , Fu D , et al. The neurobiological mechanisms and therapeutic prospect of extracellular ATP in depression . CNS Neurosci Ther . 2024 ; 30 ( 2 ): e14536 . doi: 10.1111/cns.14536 38375982 PMC10877668

165. Letavic MA , Savall BM , Allison BD , et al. 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate . J Med Chem . 2017 ; 60 ( 11 ): 4559 – 4572 . doi: 10.1021/acs.jmedchem.7b00408 28493698

166. Friedle SA , Curet MA , Watters JJ . Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation . Recent Pat CNS Drug Discov . 2010 ; 5 ( 1 ): 35 – 45 . doi: 10.2174/157488910789753530 19705995 PMC2794961

167. Chen L , Brosnan CF . Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes . J Immunol . 2006 ; 176 ( 5 ): 3115 – 3126 . doi: 10.4049/jimmunol.176.5.3115 16493071

168. Cappelli C , López X , Labra Y , et al. Polymyxin B increases the depletion of T regulatory cell induced by purinergic agonist . Immunobiology . 2012 ; 217 ( 3 ): 307 – 315 . doi: 10.1016/j.imbio.2011.10.006 22118797

169. Oyanguren-Desez O , Rodríguez-Antigüedad A , Villoslada P , Domercq M , Alberdi E , Matute C . Gain-of-function of P2X7 receptor gene variants in multiple sclerosis . Cell Calcium . 2011 ; 50 ( 5 ): 468 – 472 . doi: 10.1016/j.ceca.2011.08.002 21906809

170. Guerini FR , Agliardi C , Bolognesi E , et al. Two single nucleotide polymorphisms in the purinergic receptor P2X7 gene are associated with disease severity in multiple sclerosis . Int J Mol Sci . 2022 ; 23 ( 23 ): 15381 . doi: 10.3390/ijms232315381 36499708 PMC9736555

171. Karasawa T , Komada T , Yamada N , et al. Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome . Elife . 2022 ; 11 : e75166 . doi: 10.7554/eLife.75166 35616535 PMC9177154

172. Berkun Y , Eisenstein EM . Diagnostic criteria of familial Mediterranean fever . Autoimmun Rev . 2014 ; 13 ( 4–5 ): 388 – 390 . doi: 10.1016/j.autrev.2014.01.045 24424166

173. Jéru I . Update on the genetics of autoinflammatory disorders . Curr Allergy Asthma Rep . 2019 ; 19 ( 9 ): 41 . doi: 10.1007/s11882-019-0874-2 31321571

174. Marques-da-Silva C , Chaves MM , Castro NG , Coutinho-Silva R , Guimaraes MZ . Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action . Br J Pharmacol . 2011 ; 163 ( 5 ): 912 – 926 . doi: 10.1111/j.1476-5381.2011.01254.x 21306580 PMC3130939

175. Xia S , Zhang Z , Magupalli VG , et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1 . Nature . 2021 ; 593 ( 7860 ): 607 – 611 . doi: 10.1038/s41586-021-03478-3 33883744 PMC8588876

176. Evavold CL , Ruan J , Tan Y , Xia S , Wu H , Kagan JC . The pore-forming protein gasdermin d regulates interleukin-1 secretion from living macrophages . Immunity . 2018 ; 48 ( 1 ): 35 – 44.e6 . doi: 10.1016/j.immuni.2017.11.013 29195811 PMC5773350

177. Denton CP , Khanna D . Systemic sclerosis . Lancet . 2017 ; 390 ( 10103 ): 1685 – 1699 . doi: 10.1016/S0140-6736(17)30933-9 28413064

178. Domsic RT . European expert recommendations for managing systemic sclerosis and its complications . Nat Rev Rheumatol . 2025 ; 21 ( 3 ): 133 – 134 . doi: 10.1038/s41584-024-01205-6 39706907

179. Gentile D , Lazzerini PE , Gamberucci A , et al. Searching novel therapeutic targets for scleroderma: P2X7-receptor is up-regulated and promotes a fibrogenic phenotype in systemic sclerosis fibroblasts . Front Pharmacol . 2017 ; 8 : 638 . doi: 10.3389/fphar.2017.00638 28955239 PMC5602350

180. Sperlágh B , Illes P . P2X7 receptor: an emerging target in central nervous system diseases . Trends Pharmacol Sci . 2014 ; 35 ( 10 ): 537 – 547 . doi: 10.1016/j.tips.2014.08.002 25223574

181. Jimenez-Pacheco A , Diaz-Hernandez M , Arribas-Blázquez M , et al. Transient P2X7 receptor antagonism produces lasting reductions in spontaneous seizures and gliosis in experimental temporal lobe epilepsy . J Neurosci . 2016 ; 36 ( 22 ): 5920 – 5932 . doi: 10.1523/JNEUROSCI.4009-15.2016 27251615 PMC6601816

182. Chen J , Yao X . A contemporary review of Behcet’s syndrome . Clin Rev Allergy Immunol . 2021 ; 61 ( 3 ): 363 – 376 . doi: 10.1007/s12016-021-08864-3 34076835

183. Stirnemann J , Belmatoug N , Camou F , et al. A review of gaucher disease pathophysiology, clinical presentation and treatments . Int J Mol Sci . 2017 ; 18 ( 2 ): 441 . doi: 10.3390/ijms18020441 28218669 PMC5343975

184. Qu Y , Dubyak GR . P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways . Purinergic Sig . 2009 ; 5 ( 2 ): 163 – 173 . doi: 10.1007/s11302-009-9132-8 PMC2686822 19189228

185. Dong Z , Wei Y , Tao M , Zhang L . Activation of the purinergic receptor P2X7 improves hepatosteatosis by promoting lipophagy . FEBS Lett . 2021 ; 595 ( 22 ): 2768 – 2780 . doi: 10.1002/1873-3468.14207 34652813